Viewing Gene With Clinical Trials Data

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Report Bug Request Feature
Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol: CD52
Name: CD52 molecule
Location: 01p36.11
Locus Group: protein-coding gene
Gene Type: Protein Coding
Locus Type: gene with protein product
ID+ Clinical Trials CompTox DrugMatrix Conditions Design Enrollment Locations Outcomes
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all

Clinical Studies

NCT Number Status Brief Title View
NCT00027560 Melphalan Fludarabine and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer View
NCT00069238 Campath-1H and EPOCH to Treat Non-Hodgkins T- and NK-Cell Lymphomas View
NCT00061048 Campath-1H for Treating Adult T-Cell LeukemiaLymphoma View
NCT00079768 Alemtuzumab to Treat Sporadic Inclusion Body Myositis View
NCT00217594 A Pilot Study of Alemtuzumab CampathR in Patients With Myelodysplastic Syndrome View
NCT01680861 TacrolimusEverolimus Versus TacrolimusEnteric-Coated Mycophenolate Sodium View
NCT00001984 Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys View
NCT02689453 Subcutaneous Recombinant Human IL-15 sc rhIL-15 and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia ATL View
NCT00590460 Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia View
NCT00579137 Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders View
NCT00345345 Alemtuzumab Campath to Treat T-Large Granular Lymphocyte Leukemia View
NCT05557903 Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL View
NCT04411043 Observatory of Prolymphocytic Leukemia T View
NCT01030900 Phase II Trial of Alemtuzumab Campath and Dose-Adjusted EPOCH-Rituximab DA-EPOCH-R in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas View
NCT03806387 Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment View
NCT00214214 A Pilot Study to Determine the Safety of Campath-1H Anti-CD52 Antibody Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus View
NCT01247701 Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies View
NCT00056979 Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases View
NCT00071396 Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders View
NCT00113048 Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies View
NCT00365846 A Pilot Study to Determine the Safety of Campath-1H Anti-CD52 Therapy in Primary Renal Allograft Transplantation View
NCT00505921 Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma View
NCT00646854 Alemtuzumab and CHOP in T-cell Lymphoma View
NCT00692562 Simultaneous Islet-Kidney Transplantation in Patients of Type 1 Diabetes With End-stage Renal Disease View
NCT04557436 TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia B-ALL View
NCT01679860 Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma View
NCT01042509 Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease View
NCT01213329 Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab View
NCT05206045 Evolution of the SURvival of Patients With SEzary Syndrome SS Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies View
NCT01982175 Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia View
NCT02711202 Sequential Targeting of Cluster of Differentiation 52 CD52 and Tumor Necrosis Factor TNF Allows Early Minimization Therapy in Kidney Transplantation View
NCT04290923 Determination of Blood Tumor Cells View
NCT03132584 Cyclophosphamide and Alemtuzumab In Lymphoma View
NCT03939026 Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With RelapsedRefractory Large B Cell or Follicular Lymphoma View
NCT06500273 Consolidation of First-Line MRD Remission with Cema-cel in Patients with LBCL View
NCT00924170 Phase II Trial of LMB-2 Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia View
NCT00725231 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP View
NCT00773149 Alemtuzumab CAMPATH 1H Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia View
NCT04416984 Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With RelapsedRefractory Large B Cell Lymphoma Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma ALPHA2 View
NCT04082260 Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS Markers for Risk Stratification and Treatment Response View
NCT00246129 CamTac TrialCampath-Tacrolimus vs IL2R MoAbTacrolimusMMF in Renal Transplantation View
NCT00472433 The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias View
NCT00495755 Campath in Chronic GVHD View
NCT00637390 A Phase I Study of Alemtuzumab in Patients With Relapsed OvarianPrimary Peritoneal Cancer View